European Committee Takes a Second Look at Alzheimer's Drug

European committee takes a second look at Alzheimer’s drug and now says it should be approved
A European regulatory committee now recommends approval of the Alzheimer’s treatment lecanemab a few months after rejecting the drug.
EU regulator backs Eisai-Biogen Alzheimer's drug after initial rejection
The European Union's drugs regulator on Thursday recommended approval of Eisai and Biogen's Leqembi for some patients with early Alzheimer's disease, reversing its initial decision from four months ago.
European watchdog partially approves new Alzheimer's drug
Europe's medicines watchdog on Thursday partially approved a marketing request for a long-awaited new treatment for Alzheimer's disease, reversing an earlier decision not to give it the green light.
EU regulator reverses decision to block Alzheimer's drug lecanemab
The European Union's drugs regulator reversed its decision to block the Alzheimer's drug lecanemab, a treatment aimed at slowing cognitive decline in patients. In July, the Amsterdam-based European Medicines Agency (EMA) denied recommending approval of the drug made by Eisai and Biogen because it considered the risks - especially bleeding and swelling in the brain - to be greater than the potential benefits in a broad population.
EU drugs regulator recommends Alzheimer's drug from Eisai-Biogen
The European Union's drugs regulator on Thursday said it recommends approval of Eisai and Biogen's Leqembi in patients with early Alzheimer's disease, months after the agency first rejected the treatment.
Changing course, European regulators now say Alzheimer’s treatment Leqembi should be approved
Reversing an earlier decision, European regulators recommended that an Alzheimer’s therapy from Eisai and Biogen should be approved.
New drug targets for Alzheimer's identified from cerebrospinal fluid
A multitude of genes have been linked to the development of Alzheimer's disease. Specifically how those genes might influence ...
'We are very hopeful' | New nasal spray could delay Alzheimer's by years, researchers say
Researchers at Texas A&M University have developed a nasal spray shown to delay disease progression in animals -- fueling ...
Nasal Spray Could Delay Alzheimer's by Years
An anti-Alzheimer's nasal spray that could delay the progress of the disease by years has been developed by scientists at ...
STAT1d
Mild Alzheimer’s patients won’t save Cassava Sciences
As we count down toward the December readout of Cassava Sciences’ simufilam Phase 3 clinical trial in Alzheimer’s disease, ...
Alzheimer’s caregivers need updated drug rules to give families more time and peace | Opinion
Alzheimer’s disease robs patients of so much more than their health. It can rewire their personalities and undermine a ...
Brain Autopsies Reveal a Potential New Culprit Behind Alzheimer's
University of Washington-led research, published in 2023, discovered microglia in the brains of people with Alzheimer's ...
Alzheimer's Disease Month - Helping Those Living with the Disease
November is National Alzheimer’s Disease Month, and it’s also Caretaker Month. These two things often go hand-in-hand, but ...
Medscape6h
Infection Plus Pollution Equals Increased Alzheimer’s Risk
The AD risk factors/hits include high exposure to traffic-related air pollution (TRAP) and infections, as well as factors ...
Pharmaceutical Technology5h
EMA rethinks stance, committee now recommends Leqembi for Alzheimer’s disease
The EMA’s Committee for Medicinal Products for Human Use has issued a positive recommendation for Eisai and Biogen’s Leqembi ...